1.36
price down icon0.01%   -0.000100
after-market Dopo l'orario di chiusura: 1.43 0.07 +5.15%
loading
Precedente Chiudi:
$1.3601
Aprire:
$1.45
Volume 24 ore:
19,367
Relative Volume:
0.36
Capitalizzazione di mercato:
$7.90M
Reddito:
-
Utile/perdita netta:
$-13.32M
Rapporto P/E:
-0.2259
EPS:
-6.02
Flusso di cassa netto:
$-13.01M
1 W Prestazione:
+0.74%
1M Prestazione:
+4.62%
6M Prestazione:
-24.44%
1 anno Prestazione:
-15.00%
Intervallo 1D:
Value
$1.33
$1.45
Intervallo di 1 settimana:
Value
$1.2894
$1.45
Portata 52W:
Value
$1.145
$2.78

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Nome
Plus Therapeutics Inc
Name
Telefono
737.255.7194
Name
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Name
Dipendente
20
Name
Cinguettio
@plustxinc
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
PSTV's Discussions on Twitter

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-01-25 Iniziato Ladenburg Thalmann Buy
2020-10-16 Iniziato Maxim Group Buy

Plus Therapeutics Inc Borsa (PSTV) Ultime notizie

pulisher
07:37 AM

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire

07:37 AM
pulisher
Nov 01, 2024

Plus Therapeutics granted extension by Nasdaq - Investing.com

Nov 01, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire

Oct 29, 2024
pulisher
Oct 27, 2024

Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World

Oct 27, 2024
pulisher
Oct 24, 2024

Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart

Oct 24, 2024
pulisher
Oct 21, 2024

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network

Oct 21, 2024
pulisher
Oct 21, 2024

Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve

Oct 19, 2024
pulisher
Oct 15, 2024

Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor

Oct 15, 2024
pulisher
Oct 13, 2024

SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT

Oct 13, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian

Oct 01, 2024
pulisher
Sep 30, 2024

Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga

Sep 30, 2024
pulisher
Sep 30, 2024

The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - The New York Times

Sep 30, 2024
pulisher
Sep 24, 2024

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers

Sep 24, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance

Sep 23, 2024
pulisher
Sep 22, 2024

Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada

Sep 19, 2024
pulisher
Sep 19, 2024

From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech

Sep 19, 2024
pulisher
Sep 18, 2024

Plus Therapeutics to present at CNS Annual Meeting - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan

Sep 18, 2024
pulisher
Sep 18, 2024

Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences

Sep 18, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada

Sep 17, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director buys $6k worth of shares - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director acquires $8.5k in stock - Investing.com

Sep 17, 2024
pulisher
Sep 16, 2024

Plus Therapeutics director acquires $8.5k in stock By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer - Yahoo Finance

Sep 16, 2024
pulisher
Sep 13, 2024

Plus Therapeutics director buys $6.7k in company stock - Investing.com India

Sep 13, 2024
pulisher
Sep 13, 2024

Petersen Greg buys $16,875 worth of Plus Therapeutics shares - Investing.com India

Sep 13, 2024
pulisher
Sep 13, 2024

Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com Australia

Sep 13, 2024
pulisher
Sep 12, 2024

Elevar Therapeutics Reports Advances in HCC and Other - GlobeNewswire

Sep 12, 2024
pulisher
Sep 11, 2024

Plus Therapeutics CEO buys $9.8k in company stock - Investing.com

Sep 11, 2024
pulisher
Sep 09, 2024

With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights - STAT

Sep 09, 2024
pulisher
Sep 08, 2024

Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial - STAT

Sep 08, 2024
pulisher
Sep 07, 2024

Plus Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia

Sep 07, 2024
pulisher
Sep 06, 2024

Plus Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India

Sep 06, 2024
pulisher
Sep 06, 2024

Zenas, Bicara set out to raise $180M-plus in separate IPOs to fund autoimmune, cancer prospects - Fierce Biotech

Sep 06, 2024
pulisher
Sep 04, 2024

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 04, 2024
pulisher
Sep 04, 2024

Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $20.00 at Ascendiant Capital Markets - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Plus Therapeutics stock sees reduced target after softer-than-expected Q2 results - Investing.com

Sep 03, 2024

Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):